학술논문

Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA
Document Type
Article
Source
In: Clinical Drug Investigation. (Clinical Drug Investigation, June 2022, 42(6):501-511)
Subject
Language
English
ISSN
11791918
11732563